Diving Deeper into The Company With The Investor Deck
- CEO and Co-founder of Hemostemix Inc, Thomas Smeenk provides a high level overview of the company with the Investor Deck presentation.
Diving Into Recent News and What it Means For the Company
- Closing of private placement and how proceeds will be used.
- Expanding on the study expected for publication.
- What investors should pay attention to for the latter part of this year.
Thomas Smeenk Discusses the latest and exciting news from Hemostemix
- New publication on how NCP-01 supports brain computer interfacing
- Closing of 2 private placements and how it is being utilized
- The milestones that investors should focus on
Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s Co-Founder, CEO, and President Thomas Smeenk about the significance of engaging Dr. Chris McNorgan, Ph.D., to drive a license agreement of NCP-01 (Neural Cellular Precursors) with a neural electrode brain implant company.
Dr. McNorgan directs the Computational Cognitive Neuroscience (CCN) laboratory at the University of Buffalo and his research – the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention – is directly relatable to neural electrode-based implantation.
With Dr. McNorgan’s appointment, it brings another expert onto the team that includes Dr. Henderson, a neurosurgeon, and Dr. Inna Sorel, the mother of the invention of NCP itself, to help drive the legitimacy of licensing the NCP-01 platform. Thomas discusses the potential for licensing and partnerships to take NCP-01 to the neural electrode-based implantation market, an industry that is being led by players such as Elon Musk’s Neuralink.
NCP is a neuronal cell precursor generated from a patient’s own blood, which homes to the site of injury and regenerates the site of injury on a neuronal cell basis. Thomas explains how Hemostemix’s NCP-01 has the potential to regenerate injured neuronal cells to support the implantations of electrodes. Thomas also discusses a pre-clinical study conducted in animals using Hemostemix’s NCP-01 that showed positive results with more than 90% of the NCP color-coded cells ending up at the site of stroke, embedding at the site, and regenerating neuronal factors that would repair the site of a stroke.
Hemostemix Announces a Convertible Debenture Offering and Spin-out Plans
Co-Founder and CEO Thomas Smeenk about Hemostemix’s latest news release on offering up to 500, 5-year convertible debentures that will pay interest at 6% for US$35,000 each to raise up to US$17.5 million. Subject to patients’ compassionate exemption from regulatory approval, Thomas discusses how the debentures can be converted into an ACP-01 therapeutic production slot for the treatment of critical limb ischemia or end-stage heart failure, or converted into Hemostemix shares at the greater of $1.00 per share or the 10-day weighted average price on the day preceding conversion.
Thomas explains how Hemostemix’s ACP-01 can vastly improve the quality of life of patients suffering from end-stage critical limb ischemia and heart diseases. During the Phase II clinical trial, 43 of 46 (93.5%) ACP-01 recipients saved a limb from amputation. Thomas also provided a financing update as the company is offering 14 million common share units at $0.20 each with each unit consisting of one common share and one common share purchase warrant, exercisable at $0.65 per common share for a period of 24 months.
Finally, Thomas outlined the company’s potential plan to spin out a company that is Phase 3 clinical trial ready and will be revenue-generating with dividend capabilities to return capital to shareholders.
CEO Thomas Smeenk provides an update on ACP-01 stem cell treatment for heart disease.
Update on Hemostemix’s ACP-01 Stem Cell Treatment for Heart Disease
Co-Founder, President and CEO Thomas Smeenk about an update on their stem cell therapeutics to treat heart diseases and critical limb ischemia. Providing an update on the production timeline for ACP-01, Thomas discusses how Hemostemix has strengthened its scientific advisory board.
Thomas talks about the appointment of Dr. Nadia Giannetti and Dr. Renzo Cecere, two of the world’s top cardiovascular physicians and stem cell scientists, as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. He explains how the recent addition to its scientific advisory board is a significant validation of ACP-01 to be “a first-to-patient approved therapeutic to treat heart disease and critical limb ischemia amongst other diseases of ischemia.”
Announcing Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants.
Announcing the Incorporation of PreCerv Inc.
Market Reaction to Successful Litigation Settlement
Co-Founder, President and CEO Thomas Smeenk talks about Hemostemix achieving a major milestone this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market’s immediate positive reaction.
In the interview, Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward.
Intellectual Property Due Diligence and Data Audit Completed
Hemostemix Using Cell Therapy To Aid in the Fight Against Cardiovascular Disease
Hemostemix CEO Thomas Smeenk joined Steve Darling from Proactive to share news about the company that is using stem cell therapy to aid in a number of diseases.
Smeenk telling Proactive more about their lead product ACP-01 which is looking to treat CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients and right now is the subject of a randomized, placebo-controlled, double blind trial for safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
Smeenk also talked about what to expect this year including Phase 2 trial results.
Discussing Recent Company Updates
Hemostemix Products for Your Fountain of Youth
Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. about Hemostemix’s recent “blockbuster” news release on collaborating with world famous Dr. James Shapiro to Treat Type 1 Diabetes and about trademarking “Your Fountain of Youth”.
In this InvestorIntel interview, Thomas Smeenk said that Dr. James Shapiro is well known and respected for creating the Edmonton Protocol for the treatment of Type 1 Diabetes. Thomas went on to provide an update on Hemostemix’s technology platform that uses stem cells from a patient’s own blood to treat the heart-damage following a heart attack.
Providing an update on Hemostemix’s recently closed oversubscribed private placement, he went on to explain how Hemostemix has found a “Fountain of Youth.”
Discussing the Hiring of Dr Henderson & More Exciting Updates
Could you recover from illness… using your own stem cell?
Ted Talk by Nabiha Aaklayen
What if diseases could be treated with a patient’s own cells, precisely and on demand? Biotech entrepreneur Nabiha Saklayen explains how we could harness advances in biology, machine learning and lasers to create personalized stem cell banks — and develop medicine uniquely designed for each of our bodies.
Shaping the Future of Medicine
Hemostemix is a clinical-stage #biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.
Three months after the GCFF #healthcare event, we are excited to meet with Thomas Smeenk, CEO and Co-founder of Hemostemix again for the latest updates. On Sep 14, Hemostemix announced the first of a series of 2021 video interviews with ACP-01 recipients: what the successful compassionate treatment of ischemic cardiomyopathy looks like after 13 years.
Hemostemix’s lead technology, ACP-01, is expandable, and is a pioneering approach to the treatment of ischemic diseases. It is also undergoing a phase II clinical trial for Critical Limb Ischemia, and the result will be coming up in Q3.
Thomas shared with us some clinical trial stories in this episode as well. Watch today’s CEO Interview to learn more about Hemostemix.
Diving into Some Exciting Updates & Answering Common Questions
A Quick Update on What the Company has Been Up To
FDA Phase II clinical trial program of Hemostemix’s ACP-01
Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) about the Phase II Clinical Trial on Hemostemix’s ACP-01 which has the potential to treat patients with severe critical limb ischemia.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to say that Hemostemix is in the process of completing the source document verification. With about 60% of source documents verified, Thomas said that they expect the source document verification to be complete this year.
How Stem Cell Therapy is Proven Safe for Clinical Use
Some Reviews the Company has Received from Past Clients
Thomas Smeenk, CEO & Co-Founder, Hemostemix Inc., Canada
The most powerful and influential investors representing elite family offices travelled from around the world to convene in Monaco at Sir Anthony Ritossa’s 15th Global Family Office Investment Summit under the High Patronage of His Serene Highness Prince Albert II of Monaco.
Looking at the Current Trajectory of the Stem Cell Industry
Update From the Ritossa Global Family Office Investment Summits
Discussing the Opportunity of the Ritossa Global Family Office Investment Summits
Looking at the Current Trajectory of the Stem Cell Industry
Diving into the Intricacies of the Stem Cell Industry
The Current State of the Market
A Deep Dive on the Company
Hemostemix, Inc., (OTC Pink; HMTXF) (TSX: HEM)
Thomas Smeenk Co-Founder, President, CEO of Hemostemix, Inc., (OTC Pink; HMTXF) (TSX: HEM) presented on the Emerging Growth Conference on May 26, 2021.
Hemostemix, Inc., (OTC Pink; HMTXF) (TSX: HEM) is a winner of the World Economic Forum Technology Pioneer Award, is an autologous stem cell therapy company.
An Introduction to CEO, President, & Co Founder Thomas
Hemostemix Autologous Stem Cell Therapy and Why Some Call it ‘The Fountain of Youth’
Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), about Hemostemix’s autologous stem cell therapy and why he calls the technology “the fountain of youth.” In this InvestorIntel interview, Thomas went on to say that Hemostemix’s lead product ACP-01 works by treating ischemia (lack of blood circulation) in a patient’s body.
The technology has already been used to treat around 500 patients suffering from ischemia in the heart, arteries, and limb. He added that using the technology many patients were able to “save their limbs from otherwise certain amputations.”
Hemostemix has 91 patents including a patent on the automation of production which enables the company to scale the business “exponentially” as over a million patients lose their limbs to amputation in North America alone. The technology is now in Phase 2 clinical trial.
Thomas Smeenk of talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk talks about Hemostemix achieving a major milestone this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market’s immediate positive reaction.
In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward.
Benefits of Hemostemix Autologous Stem Cell Therapy
In this InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemix’s patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. “I have come across some good technologies and put together a team that have succeeded,” Thomas commented.
Thomas also provided an update on Hemostemix’s ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient’s own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.